Protocol: ROF-MD-07 New Investigational Medication for Severe Chronic Obstructive Pulmonary Disease (COPD)

This is a 52 week study to

evaluate the efficacy of Roflumilast 500ug on exacerbation rate in subjects with severe COPD.

  • Male/Female 40 years of age or older with diagnosis of Severe (Stage 3) to Very Severe (Stage 4) COPD.
  • At least 2 documented moderate to severe COPD exacerbations within the last 12 months.
  • Must be on Advair┬« (1 puff twice per day) or Symbicort┬« (2 puffs twice per day